Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 14420
Country/Region: Zambia
Year: 2015
Main Partner: Lusaka Provincial Health Office
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $6,343,344 Additional Pipeline Funding: $66,950

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $896,653
Care: TB/HIV (HVTB) $898,305
Care: Pediatric Care and Support (PDCS) $495,314
Laboratory Infrastructure (HLAB) $272,992
Strategic Information (HVSI) $165,983
Health Systems Strengthening (OHSS) $198,920
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $508,122
Testing: HIV Testing and Counseling (HVCT) $397,658
Sexual Prevention: Other Sexual Prevention (HVOP) $244,800
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $435,393
Treatment: Adult Treatment (HTXS) $1,479,246
Treatment: Pediatric Treatment (PDTX) $349,958
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Age/sex: <1 Female 2016 160
CARE_CURR Age/sex: <1 Male 2016 116
CARE_CURR Age/sex: 1-4 Female 2016 187
CARE_CURR Age/sex: 1-4 Male 2016 130
CARE_CURR Age/sex: 10-14 Female 2016 222
CARE_CURR Age/sex: 10-14 Male 2016 165
CARE_CURR Age/sex: 15-19 Female 2016 666
CARE_CURR Age/sex: 15-19 Male 2016 484
CARE_CURR Age/sex: 20-24 Female 2016 2,153
CARE_CURR Age/sex: 20-24 Male 2016 1,559
CARE_CURR Age/sex: 25-49 Female 2016 2,483
CARE_CURR Age/sex: 25-49 Male 2016 1,786
CARE_CURR Age/sex: 5-9 Female 2016 245
CARE_CURR Age/sex: 5-9 Male 2016 179
CARE_CURR Age/sex: 50+ Female 2016 61
CARE_CURR Age/sex: 50+ Male 2016 41
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 10,637
CARE_CURR Sum of Age/Sex disaggregates 2016 10,637
CARE_NEW Age/sex: <1 Female 2016 210
CARE_NEW Age/sex: <1 Male 2016 151
CARE_NEW Age/sex: 1-4 Female 2016 129
CARE_NEW Age/sex: 1-4 Male 2016 94
CARE_NEW Age/sex: 10-14 Female 2016 86
CARE_NEW Age/sex: 10-14 Male 2016 63
CARE_NEW Age/sex: 15-19 Female 2016 443
CARE_NEW Age/sex: 15-19 Male 2016 325
CARE_NEW Age/sex: 20-24 Female 2016 1,518
CARE_NEW Age/sex: 20-24 Male 2016 1,099
CARE_NEW Age/sex: 25-49 Female 2016 1,734
CARE_NEW Age/sex: 25-49 Male 2016 1,258
CARE_NEW Age/sex: 5-9 Female 2016 172
CARE_NEW Age/sex: 5-9 Male 2016 125
CARE_NEW Age/sex: 50+ Female 2016 47
CARE_NEW Age/sex: 50+ Male 2016 23
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 7,477
CARE_NEW Sum of Age/sex disaggregates 2016 7,477
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 2,788
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 1,898
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 20,140
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 13,152
HTS_TST By Test Result: Negative 2016 34,975
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 37,978
HTS_TST Sum of Aggregated Age/Sex <15 2016 4,686
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 33,292
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 37,978
HTS_TST Sum of Test Result disaggregates 2016 37,978
HTS_TST_POS By Test Result: Positive 2016 3,003
LAB_CAP By clinical laboratories 2016 22
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 22
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 1,096
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 1,096
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 6
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 6
PMTCT_EID Sum of Infant Age disaggregates 2016 6
PMTCT_STAT By: Known positives at entry 2016 522
PMTCT_STAT By: Known positives at entry 2016 1
PMTCT_STAT By: Number of new positives identified 2016 617
PMTCT_STAT By: Number of new positives identified 2016 2
PMTCT_STAT Number of new ANC and L&D clients 2016 20,916
PMTCT_STAT Number of new ANC and L&D clients 2016 285
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 20,916
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 285
PMTCT_STAT Sum of Positives Status disaggregates 2016 1,139
PMTCT_STAT Sum of Positives Status disaggregates 2016 3
PP_PREV Age/sex: 10-14 Female 2016 255
PP_PREV Age/sex: 10-14 Male 2016 160
PP_PREV Age/sex: 15-19 Female 2016 635
PP_PREV Age/sex: 15-19 Male 2016 400
PP_PREV Age/sex: 20-24 Female 2016 1,365
PP_PREV Age/sex: 20-24 Male 2016 918
PP_PREV Age/sex: 25-49 Female 2016 1,179
PP_PREV Age/sex: 25-49 Male 2016 762
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 5,790
PP_PREV Sum of Age/Sex disaggregates 2016 5,790
PP_PREV Total number of people in the target population 2016 5,790
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 10,637
TX_CURR Age/Sex: <1 Female 2016 64
TX_CURR Age/Sex: <1 Male 2016 54
TX_CURR Age/Sex: 1-4 Female 2016 244
TX_CURR Age/Sex: 1-4 Male 2016 156
TX_CURR Age/Sex: 5-14 Female 2016 1,870
TX_CURR Age/Sex: 5-14 Male 2016 1,246
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 28,343
TX_CURR Sum of Age/Sex disaggregations 2016 28,343
TX_NEW By Age/Sex: <1 Female 2016 168
TX_NEW By Age/Sex: <1 Male 2016 122
TX_NEW By Age/Sex: 1-4 Female 2016 112
TX_NEW By Age/Sex: 1-4 Male 2016 78
TX_NEW By Age/Sex: 10-14 Female 2016 78
TX_NEW By Age/Sex: 10-14 Male 2016 56
TX_NEW By Age/Sex: 15-19 Female 2016 376
TX_NEW By Age/Sex: 15-19 Male 2016 265
TX_NEW By Age/Sex: 20-24 Female 2016 1,260
TX_NEW By Age/Sex: 20-24 Male 2016 905
TX_NEW By Age/Sex: 25-49 Female 2016 1,457
TX_NEW By Age/Sex: 25-49 Male 2016 1,003
TX_NEW By Age/Sex: 5-9 Female 2016 147
TX_NEW By Age/Sex: 5-9 Male 2016 107
TX_NEW By Age/Sex: 50+ Female 2016 35
TX_NEW By Age/Sex: 50+ Male 2016 26
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 6,196
TX_NEW Sum of Age/Sex disaggregates 2016 6,195
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 4,822
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 4,822
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 83
VMMC_CIRC By Age: 10-14 2016 38
VMMC_CIRC By Age: 15-19 2016 119
VMMC_CIRC By Age: 20-24 2016 321
VMMC_CIRC By circumcision technique: Surgical VMMC 2016 1,073
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery 2016 211
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 862
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2016 199
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 842
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 32
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 1,073
VMMC_CIRC Sum of Age disaggregations 2016 478
Cross Cutting Budget Categories and Known Amounts Total: $10
Water $10